Literature DB >> 25460340

Simulation study for evaluating the performance of response-adaptive randomization.

Yining Du1, Xuan Wang2, J Jack Lee3.   

Abstract

A response-adaptive randomization (RAR) design refers to the method in which the probability of treatment assignment changes according to how well the treatments are performing in the trial. Holding the promise of treating more patients with the better treatments, RARs have been successfully implemented in clinical trials. We compared equal randomization (ER) with three RARs: Bayesian adaptive randomization, sequential maximum likelihood, and sequential posterior mean. We fixed the total number of patients, considered as patient horizon, but varied the number of patients in the trial. Among the designs, we compared the proportion of patients assigned to the superior arm, overall response rate, statistical power, and total patients enrolled in the trial with and without adding an efficacy early stopping rule. Without early stopping, ER is preferred when the number of patients beyond the trial is much larger than the number of patients in the trial. RAR is favored for large treatment difference or when the number of patients beyond the trial is small. With early stopping, the difference between these two types of designs was reduced. By carefully choosing the design parameters, both RAR and ER methods can achieve the desirable statistical properties. Within three RAR methods, we recommend SPM considering the larger proportion in the better arm and higher overall response rate than BAR and similar power and trial size with ER. The ultimate choice of RAR or ER methods depends on the investigator's preference, the trade-off between group ethics and individual ethics, and logistic considerations in the trial conduct, etc.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allocation probability; Bayesian adaptive design; Efficacy early stopping; Operating characteristics; Patient horizon

Mesh:

Year:  2014        PMID: 25460340      PMCID: PMC4314433          DOI: 10.1016/j.cct.2014.11.006

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  8 in total

1.  Covariate-adjusted response-adaptive designs for binary response.

Authors:  W F Rosenberger; A N Vidyashankar; D K Agarwal
Journal:  J Biopharm Stat       Date:  2001-11       Impact factor: 1.051

2.  Practical Bayesian guidelines for phase IIB clinical trials.

Authors:  P F Thall; R Simon
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

3.  Bayesian adaptive randomization designs for targeted agent development.

Authors:  J Jack Lee
Journal:  Clin Trials       Date:  2010-06-22       Impact factor: 2.486

4.  Outcome--adaptive randomization: is it useful?

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

5.  Phase II trial design with Bayesian adaptive randomization and predictive probability.

Authors:  Guosheng Yin; Nan Chen; J Jack Lee
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2012-03-01       Impact factor: 1.864

6.  A comparison of adaptive allocation rules for group-sequential binary response clinical trials.

Authors:  Caroline C Morgan; D Stephen Coad
Journal:  Stat Med       Date:  2007-04-30       Impact factor: 2.373

Review 7.  Practical Bayesian adaptive randomisation in clinical trials.

Authors:  Peter F Thall; J Kyle Wathen
Journal:  Eur J Cancer       Date:  2007-02-16       Impact factor: 9.162

8.  Worth adapting? Revisiting the usefulness of outcome-adaptive randomization.

Authors:  J Jack Lee; Nan Chen; Guosheng Yin
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

  8 in total
  5 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Commentary on Hey and Kimmelman.

Authors:  J Jack Lee
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

3.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

4.  Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.

Authors:  Louis Jacob; Maria Uvarova; Sandrine Boulet; Inva Begaj; Sylvie Chevret
Journal:  BMC Med Res Methodol       Date:  2016-06-02       Impact factor: 4.615

5.  Design and implementation of pragmatic clinical trials using the electronic medical record and an adaptive design.

Authors:  Kelly Claire Simon; Samuel Tideman; Laura Hillman; Rebekah Lai; Raman Jathar; Yuan Ji; Stuart Bergman-Bock; James Castle; Tiffani Franada; Thomas Freedom; Revital Marcus; Angela Mark; Steven Meyers; Susan Rubin; Irene Semenov; Chad Yucus; Anna Pham; Lisette Garduno; Monika Szela; Roberta Frigerio; Demetrius M Maraganore
Journal:  JAMIA Open       Date:  2018-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.